Assays and technologies for developing proteolysis targeting chimera degraders.
Future Med Chem
; 12(12): 1155-1179, 2020 06.
Article
in En
| MEDLINE
| ID: mdl-32431173
Targeted protein degradation by small-molecule degraders represents an emerging mode of action in drug discovery. Proteolysis targeting chimeras (PROTACs) are small molecules that can recruit an E3 ligase and a protein of interest (POI) into proximity, leading to induced ubiquitination and degradation of the POI by the proteasome system. To date, the design and optimization of PROTACs remain empirical due to the complicated mechanism of induced protein degradation. Nevertheless, it is increasingly appreciated that profiling step-by-step along the ubiquitin-proteasome degradation pathway using biochemical and biophysical assays are essential in understanding the structure-activity relationship and facilitating the rational design of PROTACs. This review aims to summarize these assays and to discuss the potential of expanding the toolbox with other new techniques.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Small Molecule Libraries
/
Proteolysis
Limits:
Humans
Language:
En
Journal:
Future Med Chem
Year:
2020
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom